文献速递艾滋病与性传播感染

HIV-1阳性女性妊娠起始时利匹韦林换药与否的队列研究

Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

在孕14周前已证实病毒学抑制者中,转换RFC组病毒反弹风险显著高于继续RPV组(20.0% vs 0.0%,P=0.046),分娩结局组间相似,无HIV传播。

要点

  • 孕早期已抑制者继续RPV比换药病毒反弹风险更低
  • 换药组病毒反弹20.0%,继续组0.0%,差异有统计学意义
  • 整体分娩结局相似,无HIV母婴传播

核心结论

  • 在病毒学抑制的妊娠女性中,继续利匹韦林比更换方案病毒学结局更好。
  • 未观察到继续利匹韦林增加不良妊娠结局风险。

研究设计与样本

  • 比较继续与中断利匹韦林者的妊娠结局;在孕14周前已证实病毒抑制(<50 copies/mL)者中比较病毒反弹风险。

主要发现

  • 247例中88.7%在妊娠开始时病毒学抑制。
  • 184例(74.5%)在中位孕8.0周转换为RFC,多为含PI/ritonavir方案。
  • 临近分娩时血浆HIV-1 RNA <50 copies/mL者占95.6%。
  • 孕14周前已抑制的69例中,转换RFC组病毒反弹风险高于继续RPV组(20.0% vs 0.0%,P=0.046)。
  • 分娩结局组间相似:总体出生缺陷3.8/100活产,妊娠丢失2.0%,早产10.6%,无HIV传播。

关键数值与推荐

  • 法国指南推荐妊娠期转换为不含利匹韦林的方案。
  • 孕14周前病毒抑制定义为<50 copies/mL;病毒反弹定义为≥50 copies/mL。

临床怎么用

  • 对孕早期已使用利匹韦林且病毒学抑制的女性,继续原方案可能比换药更有利于维持病毒抑制。
  • 换药决策需权衡病毒反弹风险与指南推荐,个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy. OBJECTIVES: To describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC. METHODS: In the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010-18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (<50 copies/mL) before 14 weeks of gestation (WG) while on rilpivirine, we compared the probability of viral rebound (≥50 copies/mL) during pregnancy between subjects continuing rilpivirine versus those switching to RFC. RESULTS: Among 247 women included, 88.7% had viral suppression at the beginning of pregnancy. Overall, 184 women (74.5%) switched to an RFC (mostly PI/ritonavir-based regimens) at a median gestational age of 8.0 WG. Plasma HIV-1 RNA nearest delivery was <50 copies/mL in 95.6% of women. Among 69 women with documented viral suppression before 14 WG, the risk of viral rebound was higher when switching to RFCs than when continuing rilpivirine (20.0% versus 0.0%, P = 0.046). Delivery outcomes were similar between groups (overall birth defects, 3.8/100 live births; pregnancy losses, 2.0%; preterm deliveries, 10.6%). No HIV transmission occurred. CONCLUSIONS: In virologically suppressed women initiating pregnancy, continuing rilpivirine was associated with better virological outcome than changing regimen. We did not observe a higher risk of adverse pregnancy outcomes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Frange P, Tubiana R, Sibiude J, et al. Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? J Antimicrob Chemother. 2020. PMID: 32157283. doi:10.1093/jac/dkaa017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。